Journal
CANCER IMMUNOLOGY RESEARCH
Volume 3, Issue 6, Pages 631-640Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2326-6066.CIR-14-0190
Keywords
-
Categories
Funding
- Japan Science and Technology Agency CREST program
- Japanese Ministry of Education, Culture, Sports, Science and Technology [25460491, 25293113]
- Health and Labor Science Research Grants for Research for Promotion of Cancer Control (Applied Research for Innovative Treatment of Cancer)
- Grants-in-Aid for Scientific Research [25293113, 26670326, 25460491, 24501329] Funding Source: KAKEN
Ask authors/readers for more resources
Depletion of CD4(+) cells in tumor-bearing mice has strong antitumor effects. However, the mechanisms underlying these effects and the therapeutic benefits of CD4(+) cell depletion relative to other immunotherapies have not been fully evaluated. Here, we investigated the antitumor effects of an anti-CD4-depleting mAb as a monotherapy or in combination with immune checkpoint mAbs. In B16F10, Colon 26, or Lewis lung carcinoma subcutaneous tumor models, administration of the anti-CD4 mAb alone had strong antitumor effects that were superior to those elicited by CD25(+) Treg depletion or other immune checkpoint mAbs, and which were completely reversed by CD8(+) cell depletion. CD4(+) cell depletion led to the proliferation of tumor-specific CD8(+) T cells in the draining lymph node and increased infiltration of PD-1(+)CD8(-) T cells into the tumor, with a shift toward type I immunity within the tumor. Combination treatment with the anti-CD4 mAb and immune checkpoint mAbs, particularly anti-PD-1 or anti-PD-L1 mAbs, synergistically suppressed tumor growth and greatly prolonged survival. To our knowledge, this work represents the first report of robust synergy between anti-CD4 and anti-PD-1 or anti-PD-L1 mAb therapies. (C)2015 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available